Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa.

Factors independently associated with incidence of HIVDR were: initial treatment with a didanosine (DDI)-based regimen; receiving care at township hospital or village clinic;

Among patients with virological failure on a first-line dual NRTI plus NNRTI regimen, a higher proportion of those who received TDF and/or ABC had the non-TAMs K65R, K70EQG, L74VI,

In an effort to standardize HIVDR surveillance globally and to increase survey national representativity, the WHO has proposed a comprehensive strategy including 4 proto- cols to

KEYWORDS: Human immunodeficiency virus; Anti-retroviral treatment; Resistance mutations; Highly active antiretroviral therapy; Risk factors; Response;

Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy

Absolute and cumulative prevalence of each major nucleoside (NRTI) and nonnucleoside RT inhibitor (NNRTI) drug-resistance mutation (DRM) in 4,926 individuals with virological

Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naive human immunodeficiency virus type 1-positive indivi- duals in Rio de Janeiro,

Prevalence of Protease and Reverse Transcriptase Drug Resistance Mutations over Time in Drug-Naïve Human Immunodeficiency Virus Type 1-Positive Individuals in Rio de Janeiro,